Propanc Biopharma, INC 10-Q quarterly reports

Propanc Biopharma reports a net loss of $6.36 million for the third quarter of fiscal 2026 as it continues development of its lead cancer treatment candidate, PRP.

Propanc Biopharma, Inc. reported a significant net loss of $7.9 million for the six months ended December 31, 2025, as it continues preclinical development of its cancer treatment candidate, PRP, and addresses going concern issues.

Propanc Biopharma posted a significant net loss in Q1 2026, driven by higher administrative costs, despite a successful Nasdaq listing and new patent grant.

Propanc Biopharma reports its Q3 2025 results, highlighting ongoing research and development efforts and the need for additional financing.

Propanc Biopharma reports ongoing losses for the quarter ended December 31, 2024, while implementing a reverse stock split to address listing requirements.

Propanc Biopharma's Q1 2025 report reveals ongoing financial struggles, including a net loss and a working capital deficit, alongside plans for a reverse stock split and a potential NASDAQ uplisting.

Propanc Biopharma reports its Q3 2024 results, highlighting ongoing research and development efforts while addressing significant financial challenges and a going concern qualification.

Propanc Biopharma continues its focus on developing cancer treatments, with no revenue reported for Q2 2024 as it remains in the preclinical phase.